Leeman-Neill, Rebecca

Publications

Sort by

Co-Author Network

selected publications

AID in non-Hodgkin B-cell lymphomas: The consequences of on- and off-target activity. Advances in immunology. 2024 Review GET IT
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression. Nature genetics. 2023 Academic Article GET IT
Times cited: 11
Clinical Utility and Reimbursement of Next-Generation Sequencing-Based Testing for Myeloid Malignancies. The Journal of molecular diagnostics : JMD. 2023 Academic Article GET IT
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022 Academic Article GET IT
Times cited: 16
The clinical and pathological features of plasma cell myeloma post solid organ transplantation. American journal of hematology. 2020 Academic Article GET IT
Times cited: 2
Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica. 2019 Academic Article GET IT
Times cited: 54
Co-existent pilocytic astrocytoma with acute B-cell leukemia within the cerebellum. 2019 GET IT
Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy. Leukemia research. 2019 Letter GET IT
Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 4
The Common Key to Class-Switch Recombination and Somatic Hypermutation: Discovery of AID and Its Role in Antibody Gene Diversification. Journal of immunology (Baltimore, Md. : 1950). 2018 Review GET IT
Times cited: 5
Pathogenesis of Enteropathy-Associated T Cell Lymphoma. Current hematologic malignancy reports. 2018 Review GET IT
Times cited: 46
Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer. Journal of the National Cancer Institute. 2018 Academic Article GET IT
Times cited: 52
BCL6 as a therapeutic target for lymphoma. Expert opinion on therapeutic targets. 2018 Review GET IT
Times cited: 54
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment. 2016 GET IT
Times cited: 5
Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. British journal of cancer. 2015 Academic Article GET IT
Times cited: 35
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene. British journal of haematology. 2015 Letter GET IT
Times cited: 22
ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2013 Academic Article GET IT
Times cited: 235
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013 Academic Article GET IT
Times cited: 97
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer prevention research (Philadelphia, Pa.). 2010 Academic Article GET IT
Times cited: 55
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 2010 Academic Article GET IT
Times cited: 91
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 95
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 2009 Academic Article GET IT
Times cited: 91
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular cancer therapeutics. 2009 Academic Article GET IT
Times cited: 42

more ...

less ...

Background

education and training

Ph.D., University of Pittsburgh 2010
M.D., University of Pittsburgh School of Medicine 2008
B.A., Brandeis University 2002

Contact

full name

Rebecca Leeman-Neill

primary email

rel9056@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Rebecca Leeman-Neill Associate Professor of Pathology and Laboratory Medicine (Pending Appointment at Rank)

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage